Informative Exhibition for Deprescribing Benzodiazepines

NCT06467019 | Recruiting

• 1 other identifier: CSAPG-59
• Study Type: observational
• Target: 6,410
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this trial is to determine if an interactive and informative exhibition in the waiting room of a Primary Care Clinic can reduce the use of benzodiazepines in adults. The main question it aims to answer is: • Does an interactive and informative exhibition reduce the number of participants using benzodiazepines? Researchers will compare benzodiazepine consumption before and after the interactive and informative exhibition implementation at study center. Participants will receive an informative and interactive exhibition on the risks of chronic benzodiazepine use. A single informative session on the same topic will be conducted for health professionals.

Conditions

Benzodiazepine-Related Disorders

Keywords

Benzodiazepines; Deprescriptions

Outcome Measures

Primary Outcomes (1)

• Chronic treatment with benzodiazepines

  Percentage of patients treated chronically with benzodiazepines, based on electronic prescription data.

  1 year

Study Arms (2)

Before intervention

This group will consist of patients who attended the primary care center before the implementation of the intervention.

After intervention

This group will consist of patients who will attend the primary care center after the implementation of the intervention.

Other: Informative Session

Interventions

Informative Session OTHER

The intervention consists of implementing an interactive exhibition on the risks of chronic benzodiazepine treatment in the waiting room of a primary care center. Additionally, the health professionals at the center will receive a single informative session on the same topic.

After intervention

Eligibility Criteria

• Age: 18 Years - 99 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Community population assigned to a primary care center.

You may qualify if:

• Men and women between 18 and 99 years of age.
• Attended at the Baix-a-Mar Primary Care Center during the study period.

You may not qualify if:

• Severe mental health disease
• Displaced patients or those who do not have an assigned doctor at the center.
• Participation in another study involving an experimental intervention during the period of the present study that affects benzodiazepine prescription.

Sponsors & Collaborators

• Consorci Sanitari de l'Alt Penedès i Garraf: lead

Study Sites (1)

Centro de Salud Vilanova i la Geltrú 3 Baix A Mar

Vilanova i la Geltrú, Barcelona, Spain

RECRUITING

Study Officials

• Jordi Milozzi, MD

  Centro de Salud Vilanova i la Geltrú 3 Baix A Mar-CSAPG

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Jordi Milozzi, MD

CONTACT

+34 938 10 30 03; jmilozzi@csapg.cat

Noemí Casaponsa

CONTACT

+34 938960025; recerca@csapg.cat

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: OTHER
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 14, 2024
• First Posted: June 20, 2024
• Study Start: June 13, 2024
• Primary Completion (Estimated): July 1, 2026
• Study Completion (Estimated): July 1, 2026
• Last Updated: June 26, 2025

Record last verified: 2025-06

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL, ICF
• Time Frame: After publication of main results of the study.
• Access Criteria: IPD will be shared only for scientific research purposes and following the Spanish and European Union normative law about data protection. The requirements will be directed to the IP of the study. The IP will evaluate the request to verify and evaluate the data that is requested and the purposes for which it is requested. Next, the IP will transfer the request to the promotor center the study for the final decision.

Locations

ES (1)